Medivir in brief
Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C.
We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people's lives.
About Medivir AB
Medivir is a high-growth Nordic pharmaceutical company focusing on successful research activities within the field of infectious diseases, and with a Nordic sales organisation that currently generates an annual turnover of approximately SEK 500 million. The company was founded in 1988 as a spin-off from AstraZeneca's antiviral research unit. Medivir was listed on the NASDAQ OMX, Stockholm Stock Exchange Mid Cap List for medium-sized companies in 1996.
About our research
Pharmaceutical research and development are key to Medivir's operations. We maintain a sharp focus on infectious diseases and possess cutting-edge expertise within proteases and polymerases. Medivir's research portfolio today contains nine projects, of which six are being driven in collaboration with partners. Four of these projects are within the hepatitis C segment. The protease inhibitor, simeprevir (TMC435), is in the final phase of global phase III trials.
About our pharmaceuticals
Medivir markets pharmaceutical products in the Nordics. Our product range currently comprises some 15 prescription pharmaceuticals within a number of different therapeutic areas. Medivir's sales within the Nordic region are primarily conducted through the company's wholly-owned subsidiary, BioPhausia.
The Medivir Group also includes Cross Pharma AB, a company that conducts parallel imports of original pharmaceuticals from other EU countries and markets them in Sweden.
